AR126900A1 - GENETICALLY MODIFIED CORONAVIRUS POLYPEPTIDES, POLYNUCLEOTIDES, VECTORS AND HOST CELLS, AND RELATED COMPOSITIONS - Google Patents

GENETICALLY MODIFIED CORONAVIRUS POLYPEPTIDES, POLYNUCLEOTIDES, VECTORS AND HOST CELLS, AND RELATED COMPOSITIONS

Info

Publication number
AR126900A1
AR126900A1 ARP220102318A ARP220102318A AR126900A1 AR 126900 A1 AR126900 A1 AR 126900A1 AR P220102318 A ARP220102318 A AR P220102318A AR P220102318 A ARP220102318 A AR P220102318A AR 126900 A1 AR126900 A1 AR 126900A1
Authority
AR
Argentina
Prior art keywords
seq
polypeptide
rbd
amino acid
acid sequence
Prior art date
Application number
ARP220102318A
Other languages
Spanish (es)
Inventor
Ann M Arvin
Normand Blais
Davide Corti
Colin Havenar-Daughton
Matteo Samuele Pizzuto
Lionel Sacconnay
Gyorgy Snell
Original Assignee
Humabs Biomed Sa
Vir Biotechnology Inc
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humabs Biomed Sa, Vir Biotechnology Inc, Glaxosmithkline Biologicals Sa filed Critical Humabs Biomed Sa
Publication of AR126900A1 publication Critical patent/AR126900A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4634—Antigenic peptides; polypeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se proporcionan aquí polipéptidos de coronavirus de ingeniería, polinucleótidos que codifican los polipéptidos, vectores y células huésped que comprenden los polinucleótidos y/o expresan los polipéptidos, y composiciones relacionadas. Las formas de realización divulgadas incluyen, por ejemplo, ectodominios de espiga diseñados, dominios de unión a receptores monoméricos (RBD), RBD diseñados y proteínas de fusión que comprenden uno o más de los anteriores. Reivindicación 1: Una proteína de fusión que comprende un primer polipéptido de dominio de unión al receptor (RBD) de coronavirus unido a un segundo polipéptido RBD de coronavirus, en el que, opcionalmente, el primer y/o el segundo polipéptido RBD son de un betacoronavirus, y en el que, además, opcionalmente, el primer y el segundo polipéptido RBD son de diferentes betacoronavirus. Reivindicación 40: Un polipéptido aislado que comprende: (i) SEQ ID Nº 218; (ii) SEQ ID Nº 218 sin la SEQ ID Nº 706; (iii) SEQ ID Nº 712; (iv) SEQ ID Nº 712 sin SEQ ID Nº 706; (v) SEQ ID Nº 713; (vi) SEQ ID Nº 713 sin la SEQ ID Nº 706; (vii) SEQ ID Nº 714; (viii) SEQ ID Nº 714 sin la SEQ ID Nº 706; (ix) SEQ ID Nº 715; (x) SEQ ID Nº 715 sin la SEQ ID Nº 706; (xi) SEQ ID Nº 716; (xii) SEQ ID Nº 716 sin la SEQ ID Nº 706; (xiii) SEQ ID Nº 717; (xiv) SEQ ID Nº 717 sin la SEQ ID Nº 706; (xv) SEQ ID Nº 738; (xvi) SEQ ID Nº 739; (xvii) SEQ ID Nº 740; (xviii) SEQ ID Nº 741; (xix) SEQ ID Nº 742; o (xx) SEQ ID Nº 743. Reivindicación 42: Una proteína de fusión que comprende un polipéptido del dominio de unión al receptor (RBD) del coronavirus y uno o ambos de (i) y (ii), (i) una o más etiquetas peptídicas; (ii) uno o más polipéptidos de tallo-hélice, en los que, opcionalmente, el uno o más polipéptidos de tallo-hélice comprenden o consisten en la secuencia de aminoácidos PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID Nº 701). Reivindicación 57: Un polipéptido aislado que comprende una estructura RBD1 - L1 - RBD2 - L2 - RBD3 - L3 - RBD4 - L4 - RBD5 en donde RBD1, RBD2, RBD3, RBD4 y RBD5 son cada uno un polipéptido RBD diferente seleccionado del grupo que consiste en: variante Beta del SARS-CoV-2; variante Omicron del SARS-CoV-2; variante Delta del SARS-CoV-2; PANG/GX; MP789; RaTG13; y RsSHC014, en donde RBD1 es el polipéptido RBD N-terminal de la proteína de fusión y/o RBD5 es el polipéptido RBD C-terminal de la proteína de fusión, y en donde L1, L2, L3 y L4 son cada uno un enlazador. Reivindicación 63: Un polipéptido aislado que comprende o consiste en la secuencia de aminoácidos de cualquiera de las SEQ ID Nº 701, 4 - 19, 46 y 57 - 59. Reivindicación 64: Un polipéptido aislado que comprende o consiste en la secuencia de aminoácidos de SEQ ID Nº 701, la secuencia de aminoácidos de SEQ ID Nº 14, la secuencia de aminoácidos de SEQ ID Nº 15, la secuencia de aminoácidos de SEQ ID Nº 16, o la secuencia de aminoácidos de SEQ ID Nº 17. Reivindicación 65: Un polinucleótido aislado que codifica la proteína de fusión de acuerdo con cualquiera de las reivindicaciones 1 - 39 y 42 - 56, o el polipéptido de acuerdo con cualquiera de las reivindicaciones 40, 41 y 57 - 64. Reivindicación 72: Un método para tratar, o para inducir una respuesta inmunitaria contra una infección por coronavirus en un sujeto, el método comprende administrar al sujeto una cantidad eficaz de: la proteína de fusión de acuerdo con cualquiera de las reivindicaciones 1 - 39 y 42 - 56; el polipéptido de acuerdo con cualquiera de las reivindicaciones 40, 41 y 57 - 64; el polinucleótido de acuerdo con cualquiera de las reivindicaciones 65 - 67; el vector de acuerdo con la reivindicación 68; la célula huésped de acuerdo con la reivindicación 69; o la composición de acuerdo con la reivindicación 70 o 71, en donde, opcionalmente, la infección por coronavirus comprende una infección por sarbecovirus.Provided herein are engineered coronavirus polypeptides, polynucleotides encoding the polypeptides, vectors and host cells comprising the polynucleotides and/or expressing the polypeptides, and related compositions. Disclosed embodiments include, for example, engineered spike ectodomains, monomeric receptor binding domains (RBDs), engineered RBDs, and fusion proteins comprising one or more of the above. Claim 1: A fusion protein comprising a first coronavirus receptor binding domain (RBD) polypeptide linked to a second coronavirus RBD polypeptide, wherein, optionally, the first and/or the second RBD polypeptide are from a betacoronavirus, and wherein further, optionally, the first and second RBD polypeptides are from different betacoronaviruses. Claim 40: An isolated polypeptide comprising: (i) SEQ ID NO: 218; (ii) SEQ ID No. 218 without SEQ ID No. 706; (iii) SEQ ID NO: 712; (iv) SEQ ID NO: 712 without SEQ ID NO: 706; (v) SEQ ID NO: 713; (vi) SEQ ID No. 713 without SEQ ID No. 706; (vii) SEQ ID NO: 714; (viii) SEQ ID No. 714 without SEQ ID No. 706; (ix) SEQ ID NO: 715; (x) SEQ ID NO: 715 without SEQ ID NO: 706; (xi) SEQ ID NO: 716; (xii) SEQ ID NO: 716 without SEQ ID NO: 706; (xiii) SEQ ID NO: 717; (xiv) SEQ ID No. 717 without SEQ ID No. 706; (xv) SEQ ID NO: 738; (xvi) SEQ ID NO: 739; (xvii) SEQ ID NO: 740; (xviii) SEQ ID NO: 741; (xix) SEQ ID NO: 742; or (xx) SEQ ID NO: 743. Claim 42: A fusion protein comprising a coronavirus receptor binding domain (RBD) polypeptide and one or both of (i) and (ii), (i) one or more peptide tags; (ii) one or more stem-helix polypeptides, wherein, optionally, the one or more stem-helix polypeptides comprise or consist of the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO: 701). Claim 57: An isolated polypeptide comprising a structure RBD1 - L1 - RBD2 - L2 - RBD3 - L3 - RBD4 - L4 - RBD5 wherein RBD1, RBD2, RBD3, RBD4 and RBD5 are each a different RBD polypeptide selected from the group consisting in: Beta variant of SARS-CoV-2; Omicron variant of SARS-CoV-2; Delta variant of SARS-CoV-2; PANG/GX; MP789; RaTG13; and RsSHC014, wherein RBD1 is the N-terminal RBD polypeptide of the fusion protein and/or RBD5 is the C-terminal RBD polypeptide of the fusion protein, and wherein L1, L2, L3 and L4 are each a linker . Claim 63: An isolated polypeptide comprising or consisting of the amino acid sequence of any of SEQ ID NO: 701, 4-19, 46 and 57-59. Claim 64: An isolated polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO: 701, the amino acid sequence of SEQ ID NO: 14, the amino acid sequence of SEQ ID NO: 15, the amino acid sequence of SEQ ID NO: 16, or the amino acid sequence of SEQ ID NO: 17. Claim 65: A Isolated polynucleotide encoding the fusion protein according to any of claims 1-39 and 42-56, or the polypeptide according to any of claims 40, 41 and 57-64. Claim 72: A method of treating, or to induce an immune response against a coronavirus infection in a subject, the method comprises administering to the subject an effective amount of: the fusion protein according to any of claims 1-39 and 42-56; the polypeptide according to any of claims 40, 41 and 57-64; the polynucleotide according to any of claims 65-67; the vector according to claim 68; the host cell according to claim 69; or the composition according to claim 70 or 71, wherein, optionally, the coronavirus infection comprises a sarbecovirus infection.

ARP220102318A 2021-08-27 2022-08-26 GENETICALLY MODIFIED CORONAVIRUS POLYPEPTIDES, POLYNUCLEOTIDES, VECTORS AND HOST CELLS, AND RELATED COMPOSITIONS AR126900A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163238078P 2021-08-27 2021-08-27

Publications (1)

Publication Number Publication Date
AR126900A1 true AR126900A1 (en) 2023-11-29

Family

ID=83457424

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220102318A AR126900A1 (en) 2021-08-27 2022-08-26 GENETICALLY MODIFIED CORONAVIRUS POLYPEPTIDES, POLYNUCLEOTIDES, VECTORS AND HOST CELLS, AND RELATED COMPOSITIONS

Country Status (3)

Country Link
AR (1) AR126900A1 (en)
TW (1) TW202315895A (en)
WO (1) WO2023028603A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL299630A (en) 2020-07-06 2023-03-01 Flagship Pioneering Innovations Vi Llc Antigen binding molecules targeting sars-cov-2
KR20230058434A (en) 2020-08-26 2023-05-03 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 Antigen binding molecules targeting SARS-CoV-2

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
PT1222292E (en) 1999-10-04 2005-11-30 Medicago Inc METHOD FOR REGULATING THE TRANSCRIPTION OF EXOGENEOUS GENES IN THE PRESENCE OF NITROGEN
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
DE10113776B4 (en) 2001-03-21 2012-08-09 "Iba Gmbh" Isolated streptavidin-binding, competitively elutable peptide, this comprehensive fusion peptide, nucleic acid coding therefor, expression vector, methods for producing a recombinant fusion protein and methods for detecting and / or obtaining the fusion protein
EP1633775A2 (en) * 2003-06-13 2006-03-15 Crucell Holland B.V. Antigenic peptides of sars coronavirus and uses thereof
WO2008042814A2 (en) 2006-09-29 2008-04-10 California Institute Of Technology Mart-1 t cell receptors

Also Published As

Publication number Publication date
WO2023028603A2 (en) 2023-03-02
TW202315895A (en) 2023-04-16
WO2023028603A3 (en) 2023-05-11

Similar Documents

Publication Publication Date Title
AR126900A1 (en) GENETICALLY MODIFIED CORONAVIRUS POLYPEPTIDES, POLYNUCLEOTIDES, VECTORS AND HOST CELLS, AND RELATED COMPOSITIONS
Shirayoshi et al. Cadherin cell adhesion molecules with distinct binding specificities share a common structure.
Sugino et al. Inhibin alpha-subunit monomer is present in bovine follicular fluid
Grand et al. The amino acid sequence of the troponin C-like protein (modulator protein) from bovine uterus
Kiyatkin et al. Cloning and structure of cDNA encoding α‐latrotoxin from black widow spider venom
Marquardt et al. Complete amino acid sequence of human transforming growth factor type beta 2.
Gospodarowicz [9] Isolation and characterization of acidic and basic fibroblast growth factor
Szabo et al. The bovine insulin-like growth factor (IGF) binding protein purified from conditioned medium requires the N-terminal tripeptide in IGF-1 for binding
Trainin et al. Thymic hormones: inducers and
Bulinski et al. Peptide antibody specific for the amino terminus of skeletal muscle alpha-actin.
Baglia et al. Nuclear ribonucleoprotein release and nucleoside triphosphatase activity are inhibited by antibodies directed against one nuclear matrix glycoprotein.
KR960704038A (en) Cytokines That Bind the Cell Surface Receptor Hek
Jander et al. A collagen-like glycoprotein of the extracellular matrix is the undegraded form of type VI collagen
ATE146219T1 (en) POLYPEPTIDE
Graham et al. Complete amino acid sequence of soybean leaf P21: similarity to the thaumatin-like polypeptides
Aubert-Foucher et al. Purification and characterization of native type XIV collagen.
KR960701899A (en) Protein Complexes Having Factor VIII: C Activity and Their Preparation
Lethias et al. Flexilin: A new extracellular maxtrix glycoprotein localized on collagen fibrils
Engström et al. Amino acid and cDNA sequences of lysozyme from Hyalophora cecropia
Fresco et al. Leucine periodicity of U2 small nuclear ribonucleoprotein particle (snRNP) A'protein is implicated in snRNP assembly via protein-protein interactions
Pottinger et al. The identification and purification of the heterotrimeric GTP-binding protein from squid (Loligo forbesi) photoreceptors.
KR102093093B1 (en) Composition for improving skin anti-aging
De Winter et al. Testicular Leydig cells in vitro secrete only inhibin α-subunits, whereas Leydig cell tumors can secrete bioactive inhibin
Nishio et al. Chloroplast chaperonins: evidence for heterogeneous assembly of α and β Cpn60 polypeptides into a chaperonin oligomer
Valentine-Braun et al. Epidermal growth factor (urogastrone)-mediated phosphorylation of a 35-kDa substrate in human placental membranes: relationship to the beta subunit of the guanine nucleotide regulatory complex.

Legal Events

Date Code Title Description
FB Suspension of granting procedure